Basis: Trailing twelve months (TTM). Source: stored company filings and market data; unavailable inputs remain N/A.
Is the earnings per share (EPS) high or low?
The earnings per share (EPS) of -1.07 is 40% above its 5-year average of -1.78, near the high end of its 5-year range (-2.79–-0.78).
25.69% above its 12-month average of -1.44.
Reported quarterly EPS; no daily interpolation. Q2 FY2026 (2026-06-30): -0.18.
EPS growth vs the same fiscal quarter in the prior fiscal year, last 18 comparable quarters.
EARNINGS PER SHARE (EPS)
-1.07
EARNINGS PER SHARE (EPS) AVG TTM
-1.44
EARNINGS PER SHARE (EPS) AVG 3Y
-2.10
EARNINGS PER SHARE (EPS) AVG 5Y
-1.78
EARNINGS PER SHARE (EPS) AVG 10Y
N/A
EARNINGS PER SHARE (EPS) AVG 15Y
N/A
EARNINGS PER SHARE (EPS) AVG 20Y
N/A
CURRENT VS TTM AVG
+25.69%
CURRENT VS 3Y AVG
+49.11%
CURRENT VS 5Y AVG
+39.94%
CURRENT VS 10Y AVG
N/A
CURRENT VS 15Y AVG
N/A
CURRENT VS 20Y AVG
N/A
AN2 Therapeutics, Inc.
Market Cap
$182.86M
Earnings Per Share (EPS)
-1.07
TTM Avg
-1.44
3Y Avg
-2.10
5Y Avg
-1.78
Market Cap
$181.71M
Earnings Per Share (EPS)
4.11
TTM Avg
0.53
3Y Avg
0.05
5Y Avg
-0.11
Market Cap
$183.94M
Earnings Per Share (EPS)
-1.57
TTM Avg
-5.27
3Y Avg
-99.59
5Y Avg
-93.21
Market Cap
$178.50M
Earnings Per Share (EPS)
-23.45
TTM Avg
-38.87
3Y Avg
-195.80
5Y Avg
-1526.80
Market Cap
$188.55M
Earnings Per Share (EPS)
-0.99
TTM Avg
-0.66
3Y Avg
-3.05
5Y Avg
-5.28
Market Cap
$175.48M
Earnings Per Share (EPS)
-0.41
TTM Avg
-0.39
3Y Avg
-0.36
5Y Avg
-0.55
Market Cap
$191.25M
Earnings Per Share (EPS)
-1.13
TTM Avg
-0.83
3Y Avg
-1.37
5Y Avg
-1.18
Market Cap
$173.76M
Earnings Per Share (EPS)
-0.46
TTM Avg
-0.40
3Y Avg
-0.54
5Y Avg
-0.73
Market Cap
$171.87M
Earnings Per Share (EPS)
-0.23
TTM Avg
-0.59
3Y Avg
-0.77
5Y Avg
-0.88
| NAME | MARKET CAP | EARNINGS PER SHARE (EPS) | TTM | 3Y | 5Y |
|---|---|---|---|---|---|
| AN2 Therapeutics, Inc. (ANTX) | $182.86M | -1.07 | -1.44 | -2.10 | -1.78 |
| Oramed Pharmaceuticals Inc. (ORMP)vs › | $181.71M | 4.11 | 0.53 | 0.05 | -0.11 |
| Canton Strategic Holdings Inc (CNTN)vs › | $183.94M | -1.57 | -5.27 | -99.59 | -93.21 |
| Yarrow Bioscience Inc (YARW)vs › | $178.50M | -23.45 | -38.87 | -195.80 | -1526.80 |
| Eledon Pharmaceuticals, Inc. (ELDN)vs › | $188.55M | -0.99 | -0.66 | -3.05 | -5.28 |
| Compass Therapeutics, Inc. (CMPX)vs › | $175.48M | -0.41 | -0.39 | -0.36 | -0.55 |
| RxSight, Inc. (RXST)vs › | $191.25M | -1.13 | -0.83 | -1.37 | -1.18 |
| ProQR Therapeutics N.V. (PRQR)vs › | $173.76M | -0.46 | -0.40 | -0.54 | -0.73 |
| Journey Medical Corporation (DERM)vs › | $171.87M | -0.23 | -0.59 | -0.77 | -0.88 |
| Cue Biopharma, Inc. (CUE)vs › | $173.04M | -27.00 | -15.00 | -27.00 | -32.85 |
Trailing EPS (TTM)
$-1.07
Forward EPS (Est.)
$-0.89
P/E Ratio
N/A
Formula: EPS = Net Income / Weighted Average Shares Outstanding
Why EPS matters:
EPS (Earnings Per Share) represents the portion of a company's profit allocated to each outstanding share. Higher EPS indicates greater profitability on a per-share basis.
Expanded definitions: Investopedia, Wikipedia, Corporate Finance Institute
| DATE | EARNINGS PER SHARE (EPS) |
|---|---|
| 2025-12-31 | -1.16 |
| 2024-12-31 | -1.72 |
| 2023-12-31 | -2.74 |
| 2022-12-31 | -2.79 |
| 2021-12-31 | -1.50 |
| 2020-12-31 | -0.78 |
